<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anthrax vaccine adsorbed (United States: Availability limited to request from manufacturer [individual patient] or CDC distribution from Strategic National Stockpile via local health department): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anthrax vaccine adsorbed (United States: Availability limited to request from manufacturer [individual patient] or CDC distribution from Strategic National Stockpile via local health department): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Anthrax vaccine adsorbed (United States: Availability limited to request from manufacturer [individual patient] or CDC distribution from Strategic National Stockpile via local health department): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11083" href="/d/html/11083.html" rel="external">see "Anthrax vaccine adsorbed (United States: Availability limited to request from manufacturer [individual patient] or CDC distribution from Strategic National Stockpile via local health department): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="118916" href="/d/html/118916.html" rel="external">see "Anthrax vaccine adsorbed (United States: Availability limited to request from manufacturer [individual patient] or CDC distribution from Strategic National Stockpile via local health department): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135675"><span class="drugH1">Brand Names: US</span>
<ul>
<li>BioThrax</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F135690"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vaccine;</li>
<li>
                        Vaccine, Inactivated (Bacterial)</li></ul></div>
<div class="block doa drugH1Div" id="F135677"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7de0c61-7862-480c-9524-ce271fae6ca7">Preexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexposure prophylaxis (PrEP):</b>
<b>Note:</b> If the vaccination schedule is interrupted, the series does not need to be restarted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>). IM administration is preferred; SUBQ administration may be used in persons who are at risk for hematoma formation following IM injection.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults ≤65 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM (preferred), SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Primary immunization: 0.5 mL/dose given as a 3-dose series at day 0, 1 month, and 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Booster immunization:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Persons <b>not</b> at high risk for exposure: </i>0.5 mL/dose given at 6 and 12 months after completion of the primary series and at 3-year intervals thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-24373307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-24373307'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Persons at high risk for exposure: </i>0.5 mL/dose given 6 and 12 months after completion of the primary series and at 1-year intervals thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Note: </b>If the patient <b>has </b>completed the entire priming and booster series but has <b>not</b> received a booster dose in more than 12 months, administer an IM booster dose and wait 2 weeks to enter the high-risk area. If immediate access is required, administer the booster dose and initiate postexposure prophylaxis (PEP) antibiotics for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">If a person requires immediate access to an area where <i>B. anthracis </i>is suspected to be present in the environment or be in use and they have not completed the primary and initial booster series, a transition from preexposure prophylaxis (PrEP) to postexposure prophylaxis (PEP) with anthrax vaccine adsorbed, in conjunction with antibiotics, should occur as follows (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>):</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption>
<b>Vaccine and Antibiotic Schedule for Transition from PrEP to PEP (CDC/ACIP [Bower 2019])<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Previous PrEP doses</p></th>
<th align="center">
<p style="text-indent:0em;">Interval since last dose</p></th>
<th align="center">
<p style="text-indent:0em;">PEP vaccine</p></th>
<th align="center">
<p style="text-indent:0em;">PEP antibiotics</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> For use in persons who have not completed primary and initial booster vaccination who must access an area with high risk of <i>B. anthracis</i> exposure.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">0</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">—</p></td>
<td align="center">
<p style="text-indent:0em;">Dose 1 (week 0)</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Administer until 42 days after first dose of anthrax vaccine adsorbed or 14 days after last dose, whichever occurs later.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Dose 2 (week 2)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Dose 3 (week 4)</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">1</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">—</p></td>
<td align="center">
<p style="text-indent:0em;">Dose 2 (week 0)</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Administer until 28 days after second dose of anthrax vaccine adsorbed or 14 days after the last dose, whichever occurs later.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Dose 3 (week 2)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2</p></td>
<td align="center">
<p style="text-indent:0em;">—</p></td>
<td align="center">
<p style="text-indent:0em;">Dose 3 (week 0)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer until 14 days after last dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">&gt;6 months</p></td>
<td align="center">
<p style="text-indent:0em;">Booster dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer until 14 days after booster dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">≤6 months</p></td>
<td align="center">
<p style="text-indent:0em;">No booster dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No antimicrobials needed.</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93b60915-33f1-459a-9048-b744eefca8a7">Postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postexposure prophylaxis (inhalation exposure):</b>
<b>Initiation: </b>Vaccination should begin within 10 days of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20651644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20651644'])">Ref</a></span>). Antibody titers among vaccinated persons peak at 14 days after the last administered dose and all dosing schedules maintain a high level of predicted survival through week 9 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25239484','lexi-content-ref-27155494','lexi-content-ref-27558619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25239484','lexi-content-ref-27155494','lexi-content-ref-27558619'])">Ref</a></span>). <b>Route of administration: </b>SUBQ route is preferred for PEP. In the event of a wide-area aerosolized release of <i>B. anthracis</i>, IM administration may be considered to allow for rapid and efficient administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>). <b>Concomitant antibiotics: </b>Administer with a course of appropriate antibiotics; see guidelines for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ (preferred), IM:</b> 0.5 mL/dose given at day 0, 2 weeks, and 4 weeks postexposure.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Alternative dose-sparing schedules: </i>
<b>Note: </b>If demand were to exceed supply, alternative dose-sparing regimens should be utilized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ (preferred), IM:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Two-full-dose regimen:</i> 0.5 mL/dose given as a 2-dose series at day 0 and 2 to 4 weeks postexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Three-half-dose regimen:</i> 0.25 mL/dose given as a 3-dose series at day 0, 2 weeks, and 4 weeks postexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Additional considerations for postexposure prophylaxis following occupational exposures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-20651644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-20651644'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Fully vaccinated:</i> Personnel who have completed the primary vaccination series and booster injections do not require postexposure prophylaxis if wearing protective equipment. If respiratory protection is disrupted, an appropriate course of antimicrobial therapy is recommended.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Previously unvaccinated:</i> Workers should receive the vaccine as directed per postexposure prophylaxis along with the recommended course of antimicrobial therapy.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Partially vaccinated:</i> Any person who started but did not complete the primary vaccination series should receive antibiotics to continue until 28 days after the second dose of PEP vaccine or 14 days after the last dose of PEP vaccine, whichever occurs later; and continue with the primary vaccination schedule.</p></div>
</div>
</div>
<div class="block doe drugH1Div" id="F135678"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Safety and efficacy have not been established in persons &gt;65 years of age. </p></div>
<div class="block dop drugH1Div" id="F135684"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="118916" href="/d/html/118916.html" rel="external">see "Anthrax vaccine adsorbed (United States: Availability limited to request from manufacturer [individual patient] or CDC distribution from Strategic National Stockpile via local health department): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Routine preexposure immunization with anthrax vaccine in pediatric patients is not recommended; use in pediatric patients is determined on an event-by-event basis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226','lexi-content-ref-20651644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226','lexi-content-ref-20651644'])">Ref</a></span>). Due to increased risk of adverse effects postvaccination and unknown effects on immunogenicity, anthrax vaccine should not be administered at the same time as routine childhood immunizations. Postexposure immunization with anthrax vaccine should take priority over routine childhood immunizations; any routine childhood immunization should be postponed until 4 weeks after completion of the anthrax series (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93b60915-33f1-459a-9048-b744eefca8a7">Postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postexposure prophylaxis:</b> Use should be in conjunction with public health official guidance and recommendations on an event-by-event basis; refer to guidelines provided as part of emergency use authorization (EUA) or investigational new drug (IND) application at the time of the event. Use in combination with a 60-day systemic antimicrobial course; vaccination should begin within 10 days of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 weeks, Children, and Adolescents &lt;18 years of age: Very limited data available; use in pediatric patients extrapolated from adult experience (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>). SubQ: 0.5 mL as a 3-dose series administered at 0, 2, and 4 weeks after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226','lexi-content-ref-20651644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226','lexi-content-ref-20651644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: SubQ: 0.5 mL as a 3-dose series administered at 0, 2, and 4 weeks after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20651644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20651644'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F135653"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported with IM and SUBQ administration in adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site (45% to 97%), erythema at injection site (SUBQ: 53% to 71%; IM: 15% to 48%), induration at injection site (SUBQ: 26% to 40%; IM: 7% to 23%), injection-site nodule (SUBQ: 21% to 42%; IM: 3% to 9%), injection-site pruritus (SUBQ: 3% to 26%; IM 1% to 10%), pain at injection site (12% to 22%), swelling at injection site (SUBQ: 17% to 46%; IM: 5% to 30%), tenderness at injection site (SUBQ: 48% to 72%; IM: 41% to 51%), warm sensation at injection site (SUBQ: 29% to 51%; IM: 4% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (6% to 13%), headache (2% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased range of motion (5% to 15%; arm), myalgia (3% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Axillary pain (2%; including tenderness)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, cellulitis, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, erythema multiforme, nonimmune anaphylaxis, Stevens-Johnson syndrome)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, insomnia, malaise, neuropathy (ulnar nerve), pain, paresthesia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, rhabdomyolysis, rheumatoid arthritis (Vasudev 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis (Kerrison 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms</p></div>
<div class="block coi drugH1Div" id="F135666"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Anaphylactic or anaphylactic-like reaction following a previous dose of anthrax vaccine or any component of the formulation including aluminum, benzethonium chloride, and formaldehyde.</p></div>
<div class="block war drugH1Div" id="F135650"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis or tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: Postpone administration in patients with moderate or severe acute illness (with or without fever) in preexposure vaccination programs; may administer to patients with mild acute illness (with or without fever). When used for postexposure prophylaxis, consider the benefits versus risks in patients with moderate or severe acute illness (CDC [Wright 2010]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Anthrax disease: Persons with a history of anthrax disease may have an increased risk for severe local adverse reactions from the vaccine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]). For patients at risk of hemorrhage following IM injection, the vaccine can be administered SUBQ.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]). For patients at risk of hemorrhage following IM injection, the vaccine can be administered SUBQ.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: Anthrax vaccine should not be administered with routine childhood immunization doses due to increased potential for adverse reactions and unknown effects on immunogenicity; routine childhood immunizations should be postponed until 4 weeks after completion of anthrax series (AAP [Bradley 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Consider deferring preexposure vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Safety and efficacy have not been established in adults ≥65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Packaging may contain natural latex rubber.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878329"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety data in pediatric patients are lacking; adverse effects are anticipated to be similar to those in adult patients; local adverse reaction may occur due to aluminum hydroxide excipient based on experience with other vaccines; local reactions are not a contraindication for further doses; however, they should be administered at a different site (AAP [Bradley 2014]; CDC [Wright 2010]).</p></div>
<div class="block foc drugH1Div" id="F135661"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">BioThrax: Bacillus anthracis proteins (5 mL) [contains formaldehyde solution]</p></div>
<div class="block geq drugH1Div" id="F135647"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block accres drugH1Div" id="F11216961"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">For ordering information contact the manufacturer at 866-300-7602 or http://biothrax.com/forhealthpros/clinicalInfo/ordering.aspx. A supply is also maintained in the Strategic National Stockpile for post-exposure prophylaxis in the event of a terrorist attack with anthrax. Additional information from the CDC is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Flaboratory%2Fdrugservice%2Fformulary.html&amp;token=8fUMx%2BfB4trlY8x%2FMo8Y9Ddj5kItZ1H7qlW%2Fe3GJptY28xGubTU0DXWzUi5nl8%2BCwNhzfAcY95p7Mq5fGdd6Fg%3D%3D&amp;TOPIC_ID=8625" target="_blank">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>
<div class="block adm drugH1Div" id="F135663"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Shake well before use. Do not use if discolored or contains particulate matter. Do not use the same site for more than one injection. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). If purchased under CDC contract, US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">Preexposure prophylaxis: For IM administration into the deltoid muscle; do not inject IV or intradermally. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). For patients at risk of bleeding/hematoma following IM injection, the vaccine can be administered SUBQ over the deltoid muscle.</p>
<p style="text-indent:-2em;margin-left:2em;">Postexposure prophylaxis: Administer SUBQ over the deltoid muscle. Under normal circumstances, the SUBQ route is preferred for PEP due to the faster induction of antibody production and higher subsequent antibody concentrations and 4-week survival estimates following this route of administration (Wright 2014). In the event of a wide-area aerosolized release of <i>B. </i>
<i>anthracis</i>, IM administration may be considered to allow for rapid and efficient administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612244"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Shake well before use. Do not use if discolored or contains particulate matter. Do not use the same site for more than 1 injection. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection; routine childhood immunizations should be delayed during anthrax series. To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). If purchased under CDC contract, US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">SubQ: Postexposure prophylaxis: Administer SubQ over the deltoid muscle.</p></div>
<div class="block meg drugH1Div" id="F25734185"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) should be provided to the patient/caregiver before administering each dose of this vaccine. If purchased under CDC contract, the VIS must be provided and the VIS edition date and date it was provided to the patient/caregiver should be recorded. VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fanthrax.html&amp;token=nGTrk6nnonhuku0Yq%2BnxpjgFRzAfvIqfPSpxsngjzE9qrevRFQcYAN6ez0qyP9i%2BEmyll9jaCJMfGV7PoQ8ddq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=8625" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/anthrax.html</a>.</p></div>
<div class="block use drugH1Div" id="F135662"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax prevention:</b> Active immunization against <i>Bacillus anthracis</i> in persons 18 to 65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Preexposure:</i> For preexposure prophylaxis (PrEP) of disease in persons whose occupation or other activities place them at high risk of exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">The Department of Defense requires anthrax vaccination for designated active duty and reserve personnel (DoD [Work 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination (preexposure vaccination) for the following (CDC/ACIP [Bower 2019]); CDC/ACIP [Wright 2010]):</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons who work directly with <i>B. anthracis</i> in a laboratory</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons who handle animals or animal products if they meet ≥1 of the following criteria:</p>
<p style="text-indent:-2em;margin-left:8em;">- they are handling potentially infected animals in research settings,</p>
<p style="text-indent:-2em;margin-left:8em;">- incidence of enzootic anthrax in work area is high, or</p>
<p style="text-indent:-2em;margin-left:8em;">- when animal or animal product handling standards and restrictions are not sufficient to prevent exposure</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons engaged in environmental investigations or remediation efforts</p>
<p style="text-indent:-2em;margin-left:6em;">• Military personnel as directed by the Department of Defense</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">Routine immunization for the general population is not recommended. Vaccination may be offered to emergency and other responders (eg, police and fire departments, National Guard response teams) on a voluntary basis under the direction of a comprehensive occupational health and safety program (CDC/ACIP [Bower 2019]); CDC/ACIP [Wright 2010]).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Postexposure:</i> For postexposure prophylaxis (PEP) of disease following suspected or confirmed <i>B. anthracis</i> exposure, administered in conjunction with recommended antibiotics.</p>
<p style="text-indent:-2em;margin-left:4em;">The ACIP recommends PEP after known or suspected exposure to aerosolized <i>B. anthracis</i> spores in adults 18 to 65 years of age who did not previously complete a preexposure vaccination schedule (CDC/ACIP [Bower 2019]).</p></div>
<div class="block cyt drugH1Div" id="F13298756"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F135654"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095561"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Male fertility is not affected by vaccine administration (Catherino 2005).</p></div>
<div class="block pri drugH1Div" id="F135669"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Initial data from the Department of Defense suggest the vaccine may be linked with a slightly increased number of atrial septal defects when given during the first trimester of pregnancy; however, when premature infants are excluded from analysis, the association was not statistically significant (Ryan 2008). Additional data from the Department of Defense registry has not found an increased risk of adverse pregnancy outcomes following maternal vaccination with anthrax vaccine adsorbed (CDC [Bower 2019]; Conlin 2015; Conlin 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to anthrax infection in pregnancy is limited; however, maternal infection may be associated with preterm labor and an increased risk of maternal and fetal death (Meaney-Delman 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Although anthrax vaccine may be administered during pregnancy, use in pregnant women in a preanthrax event setting, where the risk to anthrax exposure is low, is not recommended. Vaccination is not a contraindication for pregnant women at high risk for exposure (Meaney-Delman 2014). Postexposure prophylaxis is recommended using anthrax vaccine adsorbed (in combination with appropriate antibiotic therapy) in pregnant women following inhalation exposure to aerosolized <i>Bacillus anthracis</i> (CDC [Bower 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to anthrax vaccine adsorbed is ongoing. Health care providers are encouraged to enroll pregnant women exposed to this vaccine in Emergent’s vaccination pregnancy registry (1-619-553-9255).</p></div>
<div class="block brc drugH1Div" id="F135670"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if components of this vaccine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be used if administered to nursing women. Breastfeeding is not considered a contraindication to vaccination with anthrax vaccine adsorbed (Meaney-Delman 2014).</p></div>
<div class="block mop drugH1Div" id="F135658"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Observe for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F135649"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Active immunization against <i>Bacillus anthracis</i>. The vaccine is prepared from a cell-free filtrate of <i>B. anthracis</i>, but no dead or live bacteria. Completion of the entire vaccination series is required for full protection; annual boosters are required to maintain immunity. </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58186686"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Anthrax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Biothrax</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Anthrax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25239484">
<a name="25239484"></a>Bernstein DI, Jackson L, Patel SM, et al. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. <i>Vaccine</i>. 2014;32(47):6284-6293. doi:10.1016/j.vaccine.2014.08.076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/25239484/pubmed" id="25239484" target="_blank">25239484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Emergent.1">
<a name="Emergent.1"></a>BioThrax (anthrax vaccine adsorbed) [prescribing information]. Lansing, MI: Emergent BioDefense Operations Lansing; November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834290">
<a name="31834290"></a>Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019.<i> MMWR Recomm Rep</i>. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/31834290/pubmed" id="31834290" target="_blank">31834290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777226">
<a name="24777226"></a>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-1436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/24777226/pubmed" id="24777226" target="_blank">24777226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15705399">
<a name="15705399"></a>Catherino WH, Levi A, Kao TC, Leondires MP, McKeeby J, Segars JH. Anthrax vaccine does not affect semen parameters, embryo quality, or pregnancy outcome in couples with a vaccinated male military service member. <i>Fertil Steril</i>. 2005;83(2):480-483. doi:10.1016/j.fertnstert.2004.07.965<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/15705399/pubmed" id="15705399" target="_blank">15705399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28673484">
<a name="28673484"></a>Conlin AMS, Sevick CJ, Gumbs GR, Khodr ZG, Bukowinski AT. Safety of inadvertent anthrax vaccination during pregnancy: an analysis of birth defects in the U.S. military population, 2003-2010. <i>Vaccine</i>. 2017;35(34):4414-4420. doi:10.1016/j.vaccine.2017.06.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/28673484/pubmed" id="28673484" target="_blank">28673484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26049005">
<a name="26049005"></a>Conlin AM, Bukowinski AT, Gumbs GR; Department of Defense Birth and Infant Health Registry Team. Analysis of pregnancy and infant health outcomes among women in the National Smallpox Vaccine in Pregnancy Registry who received anthrax vaccine adsorbed. <i>Vaccine</i>. 2015;33(36):4387-4390. doi:10.1016/j.vaccine.2015.05.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/26049005/pubmed" id="26049005" target="_blank">26049005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11772587">
<a name="11772587"></a>Kerrison JB, Lounsbury D, Thirkill CE, Lane RG, Schatz MP, Engler RM. Optic neuritis after anthrax vaccination. <i>Ophthalmology</i>. 2002;109(1):99-104. doi:10.1016/s0161-6420(01)00844-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/11772587/pubmed" id="11772587" target="_blank">11772587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</a>. Accessed May 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2):e130611. doi:10.3201/eid2002.130611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23168771">
<a name="23168771"></a>Meaney-Delman D, Zotti ME, Rasmussen SA, et al. Anthrax cases in pregnant and postpartum women: a systematic review. <i>Obstet Gynecol</i>. 2012;120(6):1439-1449. doi:10.1097/aog.0b013e318270ec08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/23168771/pubmed" id="23168771" target="_blank">23168771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18599489">
<a name="18599489"></a>Ryan MA, Smith TC, Sevick CJ, et al. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am J Epidemiol. 2008;168(4):434-442. doi:10.1093/aje/kwn159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/18599489/pubmed" id="18599489" target="_blank">18599489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27155494">
<a name="27155494"></a>Sivko GS, Stark GV, Tordoff KP, et al. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge. <i>Vaccine</i>. 2016;34(51):6518-6528. doi:10.1016/j.vaccine.2016.04.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/27155494/pubmed" id="27155494" target="_blank">27155494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27558619">
<a name="27558619"></a>Stark GV, Sivko GS, VanRaden M, et al. Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing. <i>Vaccine</i>. 2016;34(51):6512-6517. doi:10.1016/j.vaccine.2016.06.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/27558619/pubmed" id="27558619" target="_blank">27558619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16892791">
<a name="16892791"></a>Vasudev M, Zacharisen MC. New-onset rheumatoid arthritis after anthrax vaccination. <i>Ann Allergy Asthma Immunol</i>. 2006;97(1):110-112. doi:10.1016/S1081-1206(10)61379-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/16892791/pubmed" id="16892791" target="_blank">16892791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Work.2015">
<a name="Work.2015"></a>Work RO. Clarifying guidance for smallpox and anthrax vaccine immunization programs [written communication]. US Department of Defense; November 15, 2015. https://www.health.mil/Reference-Center/Policies/2015/11/12/Clarifying-Guidance-for-Smallpox-and-Anthrax-Vaccine-Immunization-Programs
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20651644">
<a name="20651644"></a>Wright JG, Quinn CP, Shadomy S, Messonnier N; Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. <i>MMWR Recomm Rep</i>. 2010;59(RR-6):1-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/20651644/pubmed" id="20651644" target="_blank">20651644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24373307">
<a name="24373307"></a>Wright JG, Plikaytis BD, Rose CE, et al. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. <i>Vaccine</i>. 2014;32(8):1019-1028. doi:10.1016/j.vaccine.2013.10.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-vaccine-adsorbed-united-states-availability-limited-to-request-from-manufacturer-individual-patient-or-cdc-distribution-from-strategic-national-stockpile-via-local-health-department-drug-information/abstract-text/24373307/pubmed" id="24373307" target="_blank">24373307</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8625 Version 149.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
